ASH 2014: Novel biologic therapies for managing non-Hodgkin lymphoma

Prof Martin Dreyling (Ludwig-Maximilians University of Munich, Munich, Germany) at the 2014 American Society of Hematology (ASH) Annual Meeting discusses novel biologic therapies in the management of patients with non-Hodgkin lymphoma, including a phase II/III study of lenalidomide versus investigator’s choice in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

Year of Production:
Running Time:
Color/Sound:

2015
1:50
Color/Sound

Comments are closed.